In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr. Guillermo Garcia-Manero discusses how to approach the failure of hypomethylating agents (HMAs) in the treatment of myelodysplastic syndromes (MDS).
Earn accreditation for a related activity at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7221
© 2016 Imedex, LLC.
Advertisement